Pseudomonas aeruginosa (Pa), one of the most common chronic infections among people with CF, has a variety of innate and adaptive mechanisms that have allowed it to become increasingly multidrug-resistant (MDR). MDR Pa, as well as other MDR organisms in the CF lung, are associated with increased morbidity and mortality and have become a growing threat to cystic fibrosis patients worldwide.
In this issue, Dr. Claire Elson, a Pulmonary Medicine/Cystic Fibrosis Clinical Pharmacy Specialist from the University of Missouri–Kansas City School of Pharmacy, and Dr. Christopher Oermann, Cystic Fibrosis Care Center Director and Professor of Pediatrics at the UMKC School of Medicine, review the current literature describing the changing epidemiology of MDR infections, the mechanisms of MDR development in Pseudomonas aeruginosa, and potential treatment strategies.
• Discuss the changing epidemiology of multidrug-resistant infections in people with cystic fibrosis.
• Summarize the mechanisms of multidrug-resistance development in Pseudomonas aeruginosa infection in people with cystic fibrosis.
• Describe potential treatment strategies for managing multidrug-resistant Pseudomonas aeruginosa in people with cystic fibrosis.
Clinical Pharmacy Specialist, Pulmonary Medicine/Cystic Fibrosis
Children’s Mercy Kansas City
UMKC School of Pharmacy
Adjunct Professor, University of Missouri-Kansas City School of Pharmacy
Kansas City, MO
Division Director, Division of Pulmonary and Sleep Medicine
Center Director, Cystic Fibrosis Care Center
Children's Mercy Kansas City
Kansas City, MO
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: December 15, 2018
Expiration date: December 14, 2020